Psoriasis drug target offers potential for osteosarcoma

ScienceDaily | 9/18/2019 | Staff
applecup (Posted by) Level 4
In an animal model, researchers demonstrated that the immune molecule IL23 is central to the development of osteosarcoma, a cancer of the bone. By targeting IL23, study authors successfully shrank osteosarcoma tumours in mice.

The findings, published this week in Cancer Discovery, uncover an opportunity to repurpose an existing medication and bring new hope to those suffering from osteosarcoma.

Advance - Treatments - Form - Cancer - Decades

"There has been no real advance in treatments for this form of cancer in four decades -- we have uncovered a new target that we know can be modulated with existing therapy," says senior author Professor David Thomas, Garvan Cancer Research Theme Leader and Director of the Kinghorn Cancer Centre. "We hope our findings will lead to clinical trials that will provide better outcomes for patients with this rare form of cancer."

Osteosarcoma is a rare cancer, but among the ten most common cancers affecting males between ages 15 to 29, in Australia. Arising in bone, osteosarcoma is often dismissed as growing pain or injury, and in many cases only detected after it has spread to other parts of the body.

Survival - Rate - Osteosarcoma - %

The five-year survival rate of osteosarcoma remains as low as 65%.

"Our search for new potential treatments for osteosarcoma began in 2013 when we investigated genetic risk factors for this form of cancer," says first author Dr Maya Kansara, who leads the Immunobiology of Cancer Group at Garvan.

Association - Studies - US - National - Institutes

"From genome-wide association studies conducted with the U.S. National Institutes of Health we saw that variants in a gene that encodes the protein GRM4 were frequently associated with osteosarcoma."

(Excerpt) Read more at: ScienceDaily
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!